Martie Griffin
Keine laufenden Positionen mehr
Profil
Martie Griffin worked as a Director of Pharmaceutical Regulatory Monitoring at Pfizer Inc. and as a Vice President of Quality Assurance & Compliance at both Radius Health, Inc. and Micromet Holdings, Inc. Griffin also worked as a VP of Regulatory Affairs & Corporate Quality at Eloxx Pharmaceuticals, Inc. Griffin holds a Master's in Business Administration from American InterContinental University System, Inc. and an undergraduate degree from The Catholic University of America.
Ehemalige bekannte Positionen von Martie Griffin
| Unternehmen | Position | Ende |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - |
| RADIUS HEALTH, INC. | Corporate Officer/Principal | - |
Micromet Holdings, Inc.
 Micromet Holdings, Inc. Pharmaceuticals: MajorHealth Technology Micromet Holdings, Inc. was a biopharmaceutical company with a focus on the development of antibody based products for cancer and inflammatory and autoimmune diseases. The company changed its name as Micromet, Inc. and was located in Carlsbad, CA. | Corporate Officer/Principal | - |
| ELOXX PHARMACEUTICALS, INC. | General Counsel | - |
Ausbildung von Martie Griffin
| American InterContinental University System, Inc. | Masters Business Admin |
| The Catholic University of America | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| ELOXX PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Micromet Holdings, Inc.
Micromet Holdings, Inc. Pharmaceuticals: MajorHealth Technology Micromet Holdings, Inc. was a biopharmaceutical company with a focus on the development of antibody based products for cancer and inflammatory and autoimmune diseases. The company changed its name as Micromet, Inc. and was located in Carlsbad, CA. | Health Technology |